CEO bags a bargain., page-2

G'Day Apples,

I think his communique on the provisional DARRT 1 data was very satisfying to read. To my mind it was extensive and well mapped out. Connecting it to the current LuPin trial at the end, also provided an extra intriguing extra layer to think about.

Professor Kelly's reference to the journey that mCRPC patients endure, provided a dignified but also somewhat sobering account. It certainly puts some context what kind of opponent Veyonda is grappling with.

However, despite Professor Kelly increasing his holdings, the take-away messages from this blog - and the news release overall - have been met with a mute response.

But I think that Professor Kelly is targeting an audience much broader and further afield than just the ASX. Over the past year, from what I can tell just over $120m worth of stock has been traded.

But remember Novartis paid in excess of over $2 Billion for Endocyte and almost $4 Billion for Allied Accelerator Applications.

As RBx has pointed out more than once and for reasons he has already outlined, these kinds of players will be taking an active interest in the progress of Veyonda. And I suspect DARRT as much as LuPin.

They will be all ears - even if the ASX isn't - or temporarily anyway. Professor Kelly's Blog continues to lay the groundwork for the future success of our company.

I think he may have added to his holdings this week for the locals who are a little slow to catch on.